- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:26 | Transcenta Appoints Former Sino Biopharmaceutical CFO Jennie Ma | 4 | RTTNews | ||
| 14:00 | Transcenta Therapeutics Announces Appointment of Ms. Jennie Ma as Chief Financial Officer | 71 | PR Newswire | SUZHOU, China and PRINCETON, N.J., Oct. 19, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628) today announced that its Board of Directors has approved... ► Artikel lesen | |
| 12.10. | TRANSCENTA-B Granted Patent by China National Intellectual Property Administration for Anti-CLDN18.2 Antibody | 2 | AASTOCKS | ||
| 12.10. | TRANSCENTA-B (06628): VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON THE GRANT OF CHINA INVENTION PATENTS RELATED TO OSEMITAMAB (TST001) AND ITS COMPANION ... | 2 | HKEx | ||
| 30.09. | TRANSCENTA-B (06628): CANCELLATION AND GRANT OF AWARD PURSUANT TO THE SHARE INCENTIVE SCHEME | 1 | HKEx | ||
| 15.09. | TRANSCENTA-B (06628): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS | - | HKEx | ||
| 15.09. | TRANSCENTA-B (06628): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED HOLDERS | - | HKEx | ||
| TRANSCENTA Aktie jetzt für 0€ handeln | |||||
| 15.09. | TRANSCENTA-B (06628): 2026 INTERIM REPORT | 1 | HKEx | ||
| 09.09. | Transcenta, WuXi Biologics Sign HiCB Licensing Deal | 3 | Contract Pharma | ||
| 09.09. | TRANSCENTA-B (06628): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, SEPTEMBER 9, 2026 | 1 | HKEx | ||
| 09.09. | Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies | 447 | PR Newswire | PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully... ► Artikel lesen | |
| 28.08. | TRANSCENTA-B (06628): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 28.08. | TRANSCENTA-B (06628): (1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) COMPLIANCE WITH RULE 3.10(1) OF THE LISTING RULES; AND (3) GRANT OF AWARD ... | - | HKEx | ||
| 28.08. | Transcenta Holding Ltd H1 Loss Narrows | 5 | RTTNews | ||
| 28.08. | TRANSCENTA-B (06628): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 25.08. | TRANSCENTA-B (06628): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS | 1 | HKEx | ||
| 25.08. | TRANSCENTA-B (06628): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED HOLDERS | 1 | HKEx | ||
| 25.08. | TRANSCENTA-B (06628): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON WEDNESDAY, SEPTEMBER 9, 2026 | 2 | HKEx | ||
| 25.08. | TRANSCENTA-B (06628): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 25.08. | TRANSCENTA-B (06628): MAJOR TRANSACTION DISPOSAL OF CDMO ASSETS AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DISC MEDICINE | 76,56 | +34,53 % | Disc Medicine surges on late-stage trial win for lead asset developed with Roche | ||
| QIAGEN | 41,195 | -0,24 % | QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen | |
| MODERNA | 200,05 | +3,12 % | Nach 600 % mit Moderna! Cardiol Therapeutics vor Neubewertung! Analysten sehen massives Kurspotenzial! | Mit über 600 % Kursgewinn ist die Aktie von Moderna der Performance-Spitzenreiter im Nasdaq im laufenden Jahr. Damit dürfte viel Zukunftspotenzial eingepreist sein. Dies sieht auch die Citigroup so... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,625 | 0,00 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast | ||
| ARCUTIS BIOTHERAPEUTICS | 30,575 | +6,02 % | Why Is Arcutis Biotherapeutics Stock Surging Thursday? | ||
| SUMMIT THERAPEUTICS | 15,470 | +5,60 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| ERASCA | 13,420 | +0,34 % | Erasca drops after sacking COO | ||
| VERADERMICS | 117,03 | +7,54 % | Veradermics-Aktie legt kräftig zu: Haarausfall-Medikament erreicht Phase-3-Ziele | ||
| BIONTECH | 78,80 | +0,96 % | BioNTech SE: BioNTech veröffentlicht Update zur klinischen Phase-2/3-Studie des mRNA-Krebsimmuntherapiekandidaten BNT113 bei HPV16-positivem metastasiertem Kopf- und Halskrebs | Die klinische Phase-2/3-Studie AHEAD-MERIT erreichte nicht den ersten dualen primären Endpunkt des progressionsfreien Überlebens für den mRNA-Krebsimmuntherapiekandidat BNT113 in Kombination mit Pembrolizumab... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 249,26 | +3,09 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| NURIX THERAPEUTICS | 25,050 | +2,66 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| ABSCI | 8,660 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| EVOTEC | 2,624 | +1,50 % | Nicht verpassen! Krebsmedizin und Comeback-Chancen: Vidac Pharma, Bayer und Evotec im Trendcheck! | Neue Krebstherapien zielen auf medizinische Durchbrüche ab. Für Anleger ist jedoch entscheidend, wann sich Fortschritte auch in steigenden Börsenkursen widerspiegeln. Vidac Pharma befindet sich in einer... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 3,190 | +21,76 % | Paragon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock Up | WASHINGTON (dpa-AFX) - Paragon Labs announced that several former senior executives from Apogee Therapeutics (APGE) have joined its leadership team, while Alaunos Therapeutics, Inc. (TCRT) completed... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 79,30 | +0,77 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen |
TRANSCENTA HOLDING LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCENTA HOLDING LTD finden Sie auf Wallstreet Online.